Valuation: Curis, Inc.

Market Cap 3.72M 3.32M 3.06M 2.77M 5.26M 349M 5.39M 36.56M 14.57M 187M 13.97M 13.67M 588M P/E 2026 *
-0.04x
P/E 2027 * -0.13x
Enterprise Value 3.72M 3.32M 3.06M 2.77M 5.26M 349M 5.39M 36.56M 14.57M 187M 13.97M 13.67M 588M EV / Sales 2026 *
-
EV / Sales 2027 * 0.4x
Free-Float
94.23%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 59 24/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+21.93%-18.62% - - 3.72M
+2.24%+5.83%+58.47%+65.65% 66.7B
+4.66%+8.90%+14.57%+85.41% 56.88B
-0.60%+1.73%+23.48%+94.40% 56.53B
+2.97%+15.84%+27.12%+120.78% 46.49B
+2.80%+8.15%+31.19%+45.64% 44.8B
+4.42%+6.03%+218.05%+896.58% 41.59B
-0.47%+9.60%+27.53%+52.88% 35.35B
+3.80%-1.00%+95.20%+66.79% 33.29B
+0.30%+4.67%-40.38%+388.56% 25.1B
Average +4.22%+3.29%+50.58%+201.85% 45.19B
Weighted average by Cap. +2.36%+3.97%+51.42%+180.38%

Financials

2026 *2027 *
Net sales - 9.25M 8.26M 7.6M 6.9M 13.07M 867M 13.39M 90.89M 36.22M 464M 34.72M 33.98M 1.46B
Net income -52.02M -46.43M -42.73M -38.78M -73.49M -4.88B -75.31M -511M -204M -2.61B -195M -191M -8.22B -45.23M -40.37M -37.15M -33.72M -63.9M -4.24B -65.49M -444M -177M -2.27B -170M -166M -7.15B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Curis, Inc.